GLP-1 Agonist Delivery Systems
Introduction: A Therapeutic Revolution Demanding Packaging Innovation
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as one of the most transformative drug classes in modern pharmaceutical history. Originally developed for the management of type 2 diabetes, these peptide-based therapies have since expanded into obesity treatment, cardiovascular risk reduction, and are under active investigation for conditions ranging from non-alcoholic steatohepatitis (NASH) to Alzheimer’s disease. The clinical and commercial trajectory of GLP-1 agonists is nothing short of remarkable: global sales reached $39.2 billion in 2023 and are projected to hit $168 billion by 2033.
Yet the extraordinary success of this drug class has exposed a fundamental challenge: GLP-1 receptor agonists are large, peptide-based molecules that are inherently sensitive to agitation, temperature fluctuations, and interactions with container materials. Unlike small-molecule drugs that can be formulated as simple oral tablets, GLP-1 agonists require sophisticated delivery systems that protect the fragile peptide, enable precise dosing, and support patient-friendly self-administration.
For pharmaceutical packaging manufacturers like Vialab Pharmaceutical Packaging Co., Ltd. , this represents both a significant opportunity and a profound responsibility. From glass cartridges and prefilled syringes to elastomeric closures and aluminum seals, every component of a GLP-1 delivery system must be engineered to preserve peptide stability, ensure container closure integrity, and support the demanding performance requirements of pen injectors and auto-injectors.
This article explores the unique challenges of GLP-1 agonist delivery, the technologies enabling effective administration, and the packaging considerations essential to bringing these life-changing therapies to patients worldwide.
The Unique Challenges of GLP-1 Peptide Delivery
The Biological Barrier: Why Injections Are the Norm
Native GLP-1 is a peptide hormone secreted by intestinal L-cells in response to food intake. However, its therapeutic application is severely limited by an extraordinarily short half-life—mere minutes—due to rapid degradation by the enzyme dipeptidyl peptidase-IV (DPP-IV). To overcome this limitation, pharmaceutical scientists have developed synthetic GLP-1 analogs through various modification strategies, including N- and C-terminal modifications, fatty acid side chain modifications, and large molecule conjugation.
Despite these structural enhancements, GLP-1 receptor agonists remain peptide drugs that face inherent challenges: instability, susceptibility to enzymatic degradation, and potential immunogenicity. These characteristics make oral delivery extraordinarily difficult. The body’s digestive system cannot distinguish between a therapeutic peptide and a piece of food—acid and enzymes break down biological medicines the same way they would break down a steak.
As a result, the overwhelming majority of GLP-1 agonist administration is parenteral, delivered via subcutaneous injection. This creates an immediate demand for specialized delivery devices: pen injectors, auto-injectors, and cartridge systems capable of handling high-viscosity, peptide-based formulations while ensuring accurate dosing and patient comfort.
Formulation Sensitivity and Packaging Implications
GLP-1 receptor agonists present technical challenges that go well beyond those of small-molecule injectables. These peptide-based molecules are:
Sensitive to agitation: Physical stress during manufacturing, filling, shipping, and handling can induce protein aggregation, compromising drug efficacy and potentially increasing immunogenicity risk.
Temperature-sensitive: Many GLP-1 formulations require cold-chain storage and transport, placing demands on packaging systems to maintain integrity across temperature excursions.
Prone to adsorption: Peptides can adsorb to container surfaces—whether glass or polymer—leading to concentration inaccuracies and reduced therapeutic effect.
Viscous at high concentrations: As the industry moves toward higher-concentration formulations for once-weekly dosing and smaller injection volumes, packaging components must accommodate increased viscosity while maintaining consistent dose delivery.
These attributes demand primary packaging and elastomeric closures that are reformulated to minimize extractables and adsorption, preserving peptide stability over the product lifecycle.
Injectable Delivery Systems: The Current Standard
Pen Injectors: The Workhorse of GLP-1 Delivery
Pen injectors have become the predominant delivery mechanism for GLP-1 agonists, accounting for the largest segment share of the drug delivery device market. These devices offer patients a convenient, discreet, and precise way to self-administer their medication—a critical consideration for chronic conditions like diabetes and obesity that require long-term therapy.
The GLP-1 drug delivery device market was valued at $3.6 billion in 2025 and is projected to reach $13.1 billion by 2034, at a compound annual growth rate of 16.4%. Within this market, auto-injector pens held the largest share at 48.5% of total device revenue in 2025.
Pen injectors for GLP-1 agonists typically utilize 3 mL glass cartridges that conform to ISO standards. These cartridges are manufactured from Type I borosilicate glass—the gold standard for pharmaceutical packaging due to its excellent barrier properties, low extractables profile, and compatibility with peptide-based formulations. The cartridge system must maintain container closure integrity (CCI) while enabling consistent break-loose and glide force—the forces required to initiate and sustain injection.
Prefilled Syringes: An Alternative Format
Prefilled syringes offer an alternative delivery format for GLP-1 agonists, particularly when combined with auto-injector devices for enhanced patient administration. The global prefilled syringe market is experiencing significant growth, driven in part by the expanding GLP-1 drug class. These systems typically utilize 1 mL Type I glass prefilled syringes with elastomeric plungers designed for consistent performance.
Key Device Innovations
The competitive landscape for GLP-1 delivery devices is rapidly evolving. Major players like Novo Nordisk lead the market with proprietary pen platforms such as FlexTouch and SoloStar, integrated with blockbuster drugs including Ozempic, Wegovy, and Victoza. Eli Lilly and other pharmaceutical companies are similarly investing in purpose-engineered injection systems.
Recent innovations include Stevanato Group’s Deora pen injector, a multi-use, fixed-dose device featuring a pull-push mechanism designed to minimize dosing errors. Device manufacturers are also focusing on ergonomic designs that support diverse patient populations, including those with reduced grip strength, vision differences, or dexterity issues.
Beyond Injection: Emerging Delivery Modalities
Oral Delivery: The Holy Grail
Oral administration of GLP-1 agonists has long been considered the “holy grail” of peptide drug delivery. The potential benefits are substantial: enhanced patient adherence (oral formulations can improve compliance by up to 60% compared to injectable alternatives), elimination of needle anxiety, and reduced healthcare costs—oral delivery can eliminate cold chain logistics, potentially reducing overall care costs by 15–25%.
The breakthrough came in 2019, when Novo Nordisk launched Rybelsus® (oral semaglutide), the first ever oral biologic of its kind. The key to this achievement was SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), an absorption enhancer that acts as a “bodyguard” for the GLP-1 peptide. As the tablet erodes in the stomach, SNAC neutralizes the acidic gastric environment, protecting semaglutide from enzymatic degradation, and fluidizes the stomach’s lipidic membrane to increase transcellular permeability across the gastric epithelium.
Oral GLP-1 agonists are projected to generate $18 billion by 2028. However, challenges remain. Oral semaglutide relies solely on the stomach for absorption, which can be affected by gastric anatomy and physiology changes. Bioavailability remains lower than injectable formulations, and the technology has not yet been broadly replicated across other GLP-1 molecules. The FDA approved oral semaglutide for weight management in 2025, and regulatory milestones in late 2025 and early 2026—including approvals of Eli Lilly’s orforglipron—have opened entirely new delivery modalities.
Wearable Patch Injectors
Wearable patch injectors represent another frontier in GLP-1 delivery. These devices offer several advantages over traditional pen injectors: extended drug delivery over hours or days, reduced injection frequency, and enhanced patient convenience.
Companies like Vaxess Technologies are developing microarray patches capable of delivering semaglutide. Human factors studies have shown patient preference for patch-based GLP-1 delivery over traditional injections, highlighting the demand for patient-friendly delivery mechanisms that can be used from home or while traveling.
Implantable Delivery Systems
Implantable devices offer the potential for ultra-long-acting GLP-1 therapy, addressing one of the key limitations of current injectable formulations: the need for frequent (weekly or daily) dosing.
Vivani Medical is developing the NanoPortal subdermal implant—a small titanium cylinder housing a reservoir containing a high-concentration formulation of the drug, with a nanoporous membrane of titanium oxide nanotubes at one end. The device is designed to deliver drugs steadily over time, reducing the need for frequent dosing. The implant is designed to last up to six months, with treatment duration extending to nine weeks for initial candidates. This approach could dramatically improve adherence and reduce the burden of chronic GLP-1 therapy.
Nanotechnology-Enabled Delivery
Nanotechnology is opening new possibilities for GLP-1 delivery. Lipid nanoparticles, polymeric carriers, inorganic nanoparticles, and biomimetic scaffolds are being developed to improve peptide stability, prolong circulation half-life, and enable selective tissue targeting. These approaches aim to address the fundamental challenges of peptide instability and enzymatic degradation while potentially enabling new routes of administration.
Primary Packaging: The Critical Interface
The Glass vs. Polymer Debate
For injectable GLP-1 agonists, the primary container—whether cartridge or prefilled syringe—is crucial to maintaining drug safety and efficacy through filling, storage, and administration.
Type I borosilicate glass remains the industry standard for GLP-1 packaging, offering excellent barrier properties, established regulatory acceptance, and low extractables profiles. However, as GLP-1 formulations become more concentrated and more sensitive, the limitations of glass become apparent. Peptide adsorption to glass surfaces can lead to concentration inaccuracies, and the potential for delamination—glass flakes detaching from the surface—poses serious product quality risks.
Polymer-based containers, particularly those made from cyclic olefin polymer (COP), are gaining attention for their low adsorption profiles, break resistance, and compatibility with high-viscosity formulations. For GLP-1 agonists requiring cold-chain storage, polymer containers offer advantages in maintaining container closure integrity at low temperatures.
Elastomeric Components: The Seal of Quality
The elastomeric closures—rubber stoppers for cartridges and plungers for syringes—represent another critical component of GLP-1 delivery systems. These components must maintain a tight seal while enabling smooth piston movement, and they must minimize extractables and leachables that could compromise peptide stability.
Datwyler’s halobutyl-based plungers and combiseals with DuraCoat™ laminate protection are examples of purpose-built components designed for GLP-1 formulations. These advanced elastomeric solutions address the specific challenges of peptide-based drugs: consistent break-loose and glide force for accurate dosing, minimal extractables to preserve drug integrity, and compatibility with both cartridge and prefilled syringe systems.
Container Closure Integrity (CCI)
Container closure integrity is foundational to ensuring the sterility and stability of GLP-1 agonists. CCI failures can lead to microbial contamination, moisture ingress, and loss of drug potency. For self-administered therapies—where patients rely on prefilled devices without the oversight of healthcare professionals—CCI is particularly critical.
Regulatory authorities require CCI evaluation as part of stability and packaging validation. The primary packaging system must maintain integrity over the product’s shelf life, across temperature excursions during cold-chain transport, and through the mechanical stresses of patient handling and administration.
Supply Chain and Manufacturing Considerations
The Demand-Supply Gap
The explosive growth of the GLP-1 market has created significant supply constraints limiting patient access. The global prevalence of obesity now affects more than 1 billion adults, while type 2 diabetes impacts approximately 540 million individuals worldwide. Prescription volumes for GLP-1 receptor agonists increased by more than 400% between 2020 and 2025 in the United States alone.
This unprecedented demand has strained the supply chain for primary packaging components—glass cartridges, prefilled syringes, elastomeric closures, and delivery devices. Pharmaceutical manufacturers and their packaging partners must invest in capacity expansion, supply chain resilience, and manufacturing efficiency to meet patient needs.
High-Volume, High-Quality Manufacturing
GLP-1 agonists are chronic therapies administered over years or decades. This requires packaging solutions that can be produced at scale with consistent quality, and that perform reliably over the entire course of treatment.
For packaging manufacturers, this means advanced production lines with tight dimensional control, rigorous quality systems, and comprehensive documentation and traceability. Products must be designed to handle higher viscosities and control dose delivery profiles while remaining comfortable for self-administration.
Cold Chain Logistics
Many GLP-1 formulations require cold-chain storage and transport. This places additional demands on packaging systems: they must maintain integrity across temperature variations, protect the peptide from degradation, and support the logistics of temperature-controlled distribution.
Packaging partners must maintain GMP-compliant temperature-controlled storage and provide packaging solutions that support the cold chain from manufacturing through patient administration.
The Future of GLP-1 Delivery
Connected and Smart Devices
The integration of digital health features into GLP-1 delivery devices is accelerating. Connected smart injectors with Bluetooth connectivity, dose tracking, and mobile app integration are enabling more effective chronic disease management.
AI-driven platforms are revolutionizing the personalization of GLP-1 therapy by integrating electronic health records, continuous glucose monitoring, genetic information, and lifestyle data. AI-guided dosing has demonstrated 20–30% improvement in glycemic control during clinical trials. These platforms work in conjunction with CGMs and wearable devices, enabling adaptive therapy adjustments in real-time.
Dual and Triple Agonists
The pipeline for GLP-1-based therapies extends well beyond the current generation of drugs. Dual agonists (targeting both GLP-1 and GIP receptors, as with tirzepatide) and triple agonists are in development, offering enhanced efficacy for weight loss and glycemic control. These next-generation therapies may require new delivery systems optimized for higher viscosities, larger dose volumes, or different administration schedules.
Biosimilars and Generic Competition
The entry of biosimilar and generic GLP-1 drugs—exemplified by Biocon’s FDA-approved generic liraglutide in February 2026—is expected to intensify demand for lower-cost, high-volume delivery platforms. This will open new market layers in price-sensitive geographies including India, Southeast Asia, and Latin America.
For packaging manufacturers, this means developing solutions that balance cost-effectiveness with the quality and performance requirements of GLP-1 formulations. The challenge is to deliver the same peptide protection and dosing accuracy at a price point that supports broader patient access.
Conclusion: Partnering for GLP-1 Delivery Excellence
GLP-1 receptor agonists represent one of the most significant therapeutic advances of the 21st century—a drug class that is transforming the treatment of diabetes, obesity, and metabolic disease. Yet the success of these therapies depends not only on the drug molecule itself but on the delivery systems that protect it, administer it, and enable patients to incorporate it into their daily lives.
The technical demands of GLP-1 peptide delivery are substantial. These sensitive molecules require primary packaging that minimizes adsorption and extractables, delivery devices that ensure accurate dosing and comfortable self-administration, and supply chains that maintain product integrity from manufacturing through patient use.
At Vialab Pharmaceutical Packaging Co., Ltd. , we understand the unique challenges of GLP-1 agonist packaging. From Type I borosilicate glass cartridges and prefilled syringes to aluminum caps, elastomeric closures, and customized packaging solutions, every component we manufacture is engineered to meet the exacting standards that peptide-based therapies demand.
As the GLP-1 market continues its trajectory toward $168 billion and beyond, the demand for reliable, innovative packaging solutions will only intensify. The shift toward oral delivery, connected devices, and next-generation agonists presents new opportunities for packaging manufacturers to deliver components that support innovation while ensuring patient safety and therapeutic efficacy.
The future of GLP-1 therapy is precise, patient-centric, and increasingly accessible. At Vialab, we are committed to delivering the safety, reliability, and innovation that this future demands.